Nasal antibody modulates inflammatory response in COVID-19 patients in small clinical trial
A nasally administered monoclonal antibody modulated inflammatory responses in COVID-19 patients in a small clinical trial. Read More
Aiming targeted protein degradation at kinase unlocks potential way to treat Alzheimer’s
A targeted protein degrader could break apart a kinase implicated in Alzheimer’s disease to improve the cognitive abilities of patients with the neurodegenerative condition, according to a study published March 1 in ACS Central Science. Read More
At SLAS 2023, BioAuxilium Research announces expansion of TR-FRET technology portfolio
BioAuxilium Research this week announced the expansion of its no-wash Thunder time-resolved Förster resonance energy transfer (TR-FRET) technology portfolio at the annual Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in San Diego. Read More
Toxic protein linked to both muscular dystrophy and arhinia
National Institutes of Health (NIH) researchers and collaborators have found that DUX4, a toxic protein made by the body, may be responsible for two very different rare genetic disorders. The study, published on Friday in Science Advances, may eventually lead to therapies that can help people with a type of muscular dystrophy, as well as those with a facial malformation called congenital arhinia. Read More
Machine learning finds potential brain cancer drug targets in multi-omics dataset
Researchers have applied machine learning to a multi-omics dataset to identify the kinases that drive tumor growth and drug resistance in certain types of brain tumor. Read More
MIT researchers record cellular memories through protein chains
Using engineered proteins, MIT researchers have designed a system in which they can record “memories” of sequences of cellular events, such as when certain genes are activated, or how cells respond to a drug, as cells turn on series of genes and pathways in performing functions. Read More
Wyss Institute launches RNA therapeutics startup EnPlusOne Biosciences
Wyss Institute at Harvard University has partnered with Northpond Labs to launch EnPlusOne Biosciences. The startup aims to bring versatile, scalable RNA synthesis technology to market, with the goal of unlocking the development of new RNA drugs, vaccines, and gene-editing therapies. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
